{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:33:38Z","timestamp":1794918818627,"version":"4.9.1"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>\n                    Gilbert syndrome (\n                    <jats:styled-content style=\"fixed-case\">GS<\/jats:styled-content>\n                    ) is a hereditary condition that affects ~10% of the population. It is characterized by intermittent, unconjugated hyperbilirubinemia in the absence of hepatocellular damage and hemolysis. Although\n                    <jats:styled-content style=\"fixed-case\">GS<\/jats:styled-content>\n                    is often described as a benign laboratory finding, it may alter drug metabolism by decreasing the ability to conjugate drugs. Genetic polymorphisms, specifically the\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">UGT<\/jats:styled-content>\n                      1A1*28\n                    <\/jats:italic>\n                    allele, may reduce glucuronidation by 30% that severely impacts the ability to metabolize certain medications. Antineoplastic agents used in oncologic settings have toxic side effects, and alterations in metabolism may result in severe or even life\u2010threatening toxicities. Many of the drug monographs provided by manufacturers contain dose adjustment parameters for hepatic function, using serum bilirubin as a surrogate marker. However, in patients with\n                    <jats:styled-content style=\"fixed-case\">GS<\/jats:styled-content>\n                    , hepatic function remains normal in the setting of hyperbilirubinemia, and scant literature is available to provide guidance on empirical dosage adjustment. In this review, we conducted a literature search of routinely used oncology medications and assessed the need for empirical dose adjustments in the setting of\n                    <jats:styled-content style=\"fixed-case\">GS<\/jats:styled-content>\n                    .\n                  <\/jats:p>","DOI":"10.1002\/phar.1946","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T16:06:20Z","timestamp":1494518780000},"page":"956-972","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Oncology Drug Dosing in Gilbert Syndrome Associated with\n                    <scp>UGT<\/scp>\n                    1A1: A Summary of the Literature"],"prefix":"10.1002","volume":"37","author":[{"given":"Vincent H.","family":"Ha","sequence":"first","affiliation":[{"name":"Pharmacy Department Cross Cancer Institute Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jupp","sequence":"additional","affiliation":[{"name":"Pharmacy Department Foothills Medical Centre Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger Y.","family":"Tsang","sequence":"additional","affiliation":[{"name":"Department of Oncology Tom Baker Cancer Centre University of Calgary Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-011-1641-0"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2010.07.007"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511023331802"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-12-RV-096"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199708000-00001"},{"key":"e_1_2_12_7_1","unstructured":"Genetics Home Reference. Condition gene or chromosome summary: UGT1A1 gene. Bethesda MD: National Library of Medicine [reviewed 2012 February]. Available fromhttps:\/\/ghr.nlm.nih.gov\/gene\/UGT1A1#location. Accessed March 22 2017."},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm115"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.04.013"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.1999.01984.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23777"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2010.10"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008261821434"},{"key":"e_1_2_12_14_1","unstructured":"Pfizer Canada Inc.Camptosar (irinotecan hydrochloride trihydrate) package insert. Kirkland Quebec Canada;2012."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.625"},{"key":"e_1_2_12_16_1","unstructured":"Spectrum Pharmaceuticals.Beleodaq (belinostat) package insert. Irvine CA;2014."},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.589"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.11.002"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-2-162"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/28.8.502"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008316323854"},{"issue":"6","key":"e_1_2_12_22_1","first-page":"2450","article-title":"Evidence from rat hepatocytes of an unrecognized pathway of 5\u2010fluorouracil metabolism with the formation of a glucuronide derivative","volume":"45","author":"Sommadossi JP","year":"1985","journal-title":"Cancer Res"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-8910.2004.00616.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12206"},{"key":"e_1_2_12_25_1","unstructured":"Otsuka Canada Pharmaceutical Inc.Busulfex (busulfan) package insert. Saint\u2010Laurent Quebec Canada;2016."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30149-1"},{"key":"e_1_2_12_27_1","unstructured":"Pfizer Canada Inc.Methotrexate package insert. Kirkland Quebec Canada;2011."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054528"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25457"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605653"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt394"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1096-4"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0562-5"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-14-RG-031"},{"issue":"21","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1182\/blood.V124.21.5538.5538","article-title":"Polymorphism of UGT1A1 and frequency of hyperbilirubinemia in patients with chronic myeloid leukemia treated by Nilotinib","volume":"124","author":"Bykova A","year":"2014","journal-title":"Blood"},{"issue":"23","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1182\/blood.V126.23.2795.2795","article-title":"The association of Gilbert's syndrome with hyperbilirubinaemia occurring on any of imatinib, dasatinib and nilotinib in patients with chronic myeloid leukaemia (CML)","volume":"126","author":"Bahk J","year":"2015","journal-title":"Blood"},{"key":"e_1_2_12_37_1","unstructured":"GlaxoSmithKline Inc.Votrient (pazopanib) package insert. Mississauga Ontario Canada;2015."},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2484"},{"key":"e_1_2_12_39_1","unstructured":"Novartis Pharmaceuticals Canada Inc.Tasigna (nilotinib) package insert. Dorval Quebec Canada;2016."},{"key":"e_1_2_12_40_1","unstructured":"Pfizer Canada Inc.Doxorubicin package insert. Kirkland Quebec Canada;2014."},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17334"},{"issue":"4","key":"e_1_2_12_42_1","first-page":"s12","article-title":"UGT1A1 gene pharmacogenetics in the treatment of Hodgkin's lymphoma","volume":"95","author":"Esquirol A","year":"2010","journal-title":"Haematologica"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-148874"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212439492"},{"key":"e_1_2_12_45_1","unstructured":"Celgene Corporation.Revlimid (lenalidomide) package insert. Mississauga Ontario Canada;2016."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840010213"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.014"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155207081133"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1946","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:53:22Z","timestamp":1761047602000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1002\/phar.1946"],"URL":"https:\/\/doi.org\/10.1002\/phar.1946","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]},"assertion":[{"value":"2017-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}